View Older Stories View More Recent Stories

Dec 2, 2022 04:30PM Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Dec 2, 2022 07:12AM Anavex Life Sciences (AVXL) Phase 2b/3 of ANAVEX 2-73 in Early Alzheimer's Disease Met Primary and Key Secondary Endpoints
Dec 1, 2022 08:26PM ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early
Nov 28, 2022 07:00AM Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 23, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Nov 8, 2022 07:00AM Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022
Nov 7, 2022 07:04AM Anavex Life Sciences (AVXL) Granted FDA Orphan Drug Designation for ANAVEX2-73
Nov 7, 2022 07:00AM Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
Oct 17, 2022 07:05AM Anavex Life Sciences (AVXL) Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming CTAD Congress
Oct 17, 2022 07:00AM Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Diseas
Sep 21, 2022 07:03AM Anavex Life Sciences (AVXL) Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Sep 21, 2022 07:00AM Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Aug 23, 2022 07:00AM Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
Aug 9, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
Aug 3, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
Aug 2, 2022 07:04AM Anavex Life Sciences (AVXL) Reports Long-lasting Effect of ANAVEX3-71 Preventing Cognitive Decline
Aug 2, 2022 07:00AM Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
Jul 31, 2022 10:00AM Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jun 21, 2022 08:00AM Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 8, 2022 07:03AM Anavex Life Sciences (AVXL) Reports Publication Supporting Clinical Biomarker for ANAVEX2-73 in Fragile X Syndrome
Jun 8, 2022 07:00AM Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
May 19, 2022 07:00AM Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
May 10, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
May 3, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
Apr 27, 2022 07:00AM Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Apr 26, 2022 07:00AM Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Apr 7, 2022 07:00AM Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
Mar 28, 2022 07:00AM Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
Mar 15, 2022 07:00AM Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Mar 9, 2022 07:00AM Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
Mar 4, 2022 07:06AM Anavex Life Sciences (AVXL) Announces Change of Auditor to Grant Thornton LLP
Mar 4, 2022 07:00AM Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
Feb 10, 2022 07:00AM Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 9, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results
Feb 4, 2022 07:01AM Anavex Life Sciences (AVXL) Provides Supplemental Information on ANAVEX 2-73 Phase 3 Trial
Feb 4, 2022 07:00AM Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Feb 3, 2022 07:00AM Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022
Feb 1, 2022 07:03AM Anavex Life Sciences (AVXL) Reports ANAVEX2-73 AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Feb 1, 2022 07:00AM ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Jan 10, 2022 07:00AM Anavex Life Sciences (AVXL) Reports Positive Phase 1 ANAVEX Results
Jan 10, 2022 07:00AM Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Jan 6, 2022 07:00AM Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
Jan 5, 2022 07:00AM Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dec 14, 2021 07:00AM Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Nov 29, 2021 07:00AM Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
Nov 24, 2021 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
Nov 17, 2021 07:00AM Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
Nov 10, 2021 07:00AM Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
Oct 15, 2021 07:00AM Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
Oct 13, 2021 07:05AM Anavex Life Sciences (AVXL) Announces Data Review by Independent Board of its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
View More Recent Stories View Older Stories